PubMed:33012858
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 53-61 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 180-188 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 51-52 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 143-148 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | faced |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1 | 53-63 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3 | 180-190 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-72 | Sentence | denotes | Melanie Saville: the end-to-end process needed for a SARS-CoV-2 vaccine. |
T2 | 73-265 | Sentence | denotes | Melanie Saville talks to Gary Humphreys about the specific challenges faced in developing and distributing SARS-CoV-2 vaccines and the need to fund end-to-end approaches to support those aims. |